{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:08:45Z","timestamp":1791065325442,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jaad.2025.10.015","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:17:05Z","timestamp":1759731425000},"page":"530-538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1\/2 ligands, in adults with hidradenitis suppurativa"],"prefix":"10.1016","volume":"94","author":[{"given":"Seth","family":"Forman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipak R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B.","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarannum","family":"Jaleel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Laquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Nirula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Klekotka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10476","key":"10.1016\/j.jaad.2025.10.015_bib1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","article-title":"Hidradenitis suppurativa","volume":"405","author":"Sabat","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaad.2025.10.015_bib2","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaci.2022.02.003","article-title":"Insights into hidradenitis suppurativa","volume":"149","author":"van Straalen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.015_bib3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2340\/00015555-1082","article-title":"Psychosocial impact of hidradenitis suppurativa: a qualitative study","volume":"91","author":"Esmann","year":"2011","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.015_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2025.10.015_bib5","article-title":"The pathogenesis and treatment of hidradenitis suppurativa","volume":"15","author":"Agnese","year":"2023","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.jaad.2025.10.015_bib6","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.3390\/ijms23073753","article-title":"New and emerging targeted therapies for hidradenitis suppurativa","volume":"23","author":"Markota \u010cagalj","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2025.10.015_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/2040622319830646","article-title":"Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms","volume":"10","author":"Frew","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.015_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.015_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1831880","article-title":"Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody","volume":"12","author":"Boyles","year":"2020","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.015_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2024.21972","article-title":"World medical association declaration of helsinki: ethical principles for medical research involving human participants","volume":"333","year":"2025","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.015_bib14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the hidradenitis suppurativa clinical response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.10.015_bib15","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the international hidradenitis suppurativa severity score system (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.015_bib16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology life quality index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"Suppl_3","key":"10.1016\/j.jaad.2025.10.015_bib17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/bjd\/ljad375","article-title":"Addressing high placebo response rates in randomized clinical trials for hidradenitis suppurativa","volume":"190","author":"Garg","year":"2024","journal-title":"Br J Dermatol"},{"issue":"Suppl_1","key":"10.1016\/j.jaad.2025.10.015_bib18","doi-asserted-by":"crossref","first-page":"i15","DOI":"10.1093\/bjd\/ljae318","article-title":"An evolutionary tale on clinical trials in hidradenitis suppurativa","volume":"192","author":"Sayed","year":"2025","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2025.10.015_bib19","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.015_bib20","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jaad.2024.12.046","article-title":"Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: results from a phase 2, randomized, placebo-controlled study","volume":"92","author":"Ackerman","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.015_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrd1927","article-title":"Bayesian clinical trials","volume":"5","author":"Berry","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.015_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41573-023-00638-0","article-title":"Application of bayesian approaches in drug development: starting a virtuous cycle","volume":"22","author":"Ruberg","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.jaad.2025.10.015_bib23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.jaad.2025.10.015_bib24","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1002\/sim.3722","article-title":"A note on the power prior","volume":"28","author":"Neuenschwander","year":"2009","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.015_bib25","first-page":"46","article-title":"Power prior distributions for regression models","volume":"15","author":"Ibrahim","year":"2000","journal-title":"Stat Sci"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.015_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/env.752","article-title":"Evaluating water quality using power priors to incorporate historical information","volume":"17","author":"Duan","year":"2006","journal-title":"Environmetrics"},{"issue":"10378","key":"10.1016\/j.jaad.2025.10.015_bib27","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"issue":"10443","key":"10.1016\/j.jaad.2025.10.015_bib28","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225029640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225029640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:58:10Z","timestamp":1780909090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225029640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0190962225029640"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.10.015","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1\/2 ligands, in adults with hidradenitis suppurativa","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}